This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gill, E. A. Articles by Horwitz, L. D. Search for Related Content PubMed PubMed Citation Articles by Gill, E. A. Articles by Horwitz, L. D. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Heart Attack

(Circulation. 1996;94:542-546.)
© 1996 American Heart Association, Inc.

Articles

An Oligosaccharide Sialyl-Lewis^x Analogue Does Not Reduce Myocardial Infarct Size After Ischemia and Reperfusion in Dogs

Edward A. Gill, MD; Yinong Kong, MD; Lawrence D. Horwitz, MD

the Division of Cardiology, University of Colorado Health Sciences Center (Denver).

Correspondence to Dr Edward A. Gill, Division of Cardiology, Box B130, University of Colorado Health Sciences Center, Denver, CO 80262. E-mail Ed.Gill@uchsc.edu.

Background Polymorphonuclear leukocytes, particularly neutrophils, are important mediators of ischemia/reperfusion–induced myocardial and coronary vascular injury. The selectin family of glycoprotein receptors mediates neutrophil "rolling," a loose, transient adhesion to the coronary endothelium that precedes the firmer adhesion associated with cardiovascular injury. The oligosaccharide sialyl-Lewis^x (SLe^x) is the probable neutrophil counterligand for endothelial E- and P-selectin. Administration of analogues of SLe^x could potentially prevent neutrophil rolling by competing for the selectin-adhesion sites. We investigated the effects of treatment with an analogue of SLe^x in a chronic canine model of ischemia/reperfusion.

Methods and Results Anesthetized mongrel dogs were subjected to 90 minutes of ischemia through occlusion of the left anterior descending coronary artery and 48 hours of reperfusion. Five minutes before the onset of reperfusion, dogs received either the SLe^x analogue CY-1503 at a dose of 20 mg/kg or normal saline. Myocardial infarct size was measured through triphenyltetrazolium chloride staining, and polymorphonuclear leukocyte accumulation was evaluated through measurement of cardiac myeloperoxidase activity. After adjustment for blood flow, the mean infarct size of control dogs (44.7±4.2%) was not different from that of treated dogs (33.4±4.0%, P=.06), although there was a trend toward a slightly lower value in the treated dogs. Myeloperoxidase activity was not different in the infarcted myocardium of the treated group compared with that of the control group (2.7±0.71 treated versus 1.08±0.41 units/mg protein control, P=.06).

Conclusions We conclude that CY-1503 does not substantially or consistently reduce myocardial infarct size or neutrophil accumulation in dogs subjected to ischemia followed by a prolonged period (48 hours) of reperfusion.

Key Words: reperfusion • leukocytes • myocardial infarction

This article has been cited by other articles:

				M. Horiba, K. Kadomatsu, K. Yasui, J.-K. Lee, H. Takenaka, A. Sumida, K. Kamiya, S. Chen, S. Sakuma, T. Muramatsu, et al. Midkine Plays a Protective Role Against Cardiac Ischemia/Reperfusion Injury Through a Reduction of Apoptotic Reaction Circulation, October 17, 2006; 114(16): 1713 - 1720. [Abstract] [Full Text] [PDF]

				J. Vinten-Johansen Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury Cardiovasc Res, February 15, 2004; 61(3): 481 - 497. [Abstract] [Full Text] [PDF]

				S. P. Jones, S. D. Trocha, M. B. Strange, D. N. Granger, C. G. Kevil, D. C. Bullard, and D. J. Lefer Leukocyte and endothelial cell adhesion molecules in a chronic murine model of myocardial reperfusion injury Am J Physiol Heart Circ Physiol, November 1, 2000; 279(5): H2196 - H2201. [Abstract] [Full Text] [PDF]

				M. R. Hoffmeyer, S. P. Jones, C. R. Ross, B. Sharp, M. B. Grisham, F. S. Laroux, T. J. Stalker, R. Scalia, and D. J. Lefer Myocardial Ischemia/Reperfusion Injury in NADPH Oxidase-Deficient Mice Circ. Res., October 27, 2000; 87(9): 812 - 817. [Abstract] [Full Text] [PDF]

				J. E. Jordan, Z.-Q. Zhao, and J. Vinten-Johansen The role of neutrophils in myocardial ischemia-reperfusion injury Cardiovasc Res, September 1, 1999; 43(4): 860 - 878. [Abstract] [Full Text] [PDF]

				T. Shin'oka, M. Nagashima, G. Nollert, D. Shum-Tim, P. C. Laussen, H. G. W. Lidov, A. d. Plessis, and R. A. Jonas A NOVEL SIALYL LEWIS X ANALOG ATTENUATES CEREBRAL INJURY AFTER DEEP HYPOTHERMIC CIRCULATORY ARREST J. Thorac. Cardiovasc. Surg., June 1, 1999; 117(6): 1204 - 1211. [Abstract] [Full Text] [PDF]

				C. Kupatt, H. Habazettl, A. Goedecke, D. A. Wolf, S. Zahler, P. Boekstegers, R. A. Kelly, and B. F. Becker Tumor Necrosis Factor-{alpha} Contributes to Ischemia- and Reperfusion-Induced Endothelial Activation in Isolated Hearts Circ. Res., March 5, 1999; 84(4): 392 - 400. [Abstract] [Full Text] [PDF]

				A. J. Palazzo, S. P. Jones, D. C. Anderson, D. N. Granger, and D. J. Lefer Coronary endothelial P-selectin in pathogenesis of myocardial ischemia-reperfusion injury Am J Physiol Heart Circ Physiol, November 1, 1998; 275(5): H1865 - H1872. [Abstract] [Full Text] [PDF]

				S. C. Makrides Therapeutic Inhibition of the Complement System Pharmacol. Rev., March 1, 1998; 50(1): 59 - 88. [Abstract] [Full Text] [PDF]